本文選題：芪癀膠囊　切入點(diǎn)：骨肉瘤　出處：《福建中醫(yī)藥大學(xué)》2014年碩士論文

【摘要】：目的：觀察芪癀膠囊對(duì)裸鼠原位移植骨肉瘤生長(zhǎng)的作用,并探討其機(jī)制,為扶正祛邪法應(yīng)用于骨肉瘤治療提供依據(jù)。 方法：采用32只4周齡BALB/c-nu/nu裸鼠,麻醉后右側(cè)脛骨注射JMR106-01細(xì)胞懸液(5×106個(gè)/100μl)制成骨肉瘤原位移植模型,模型鑒定成功后隨機(jī)分為四組：生理鹽水組(1ml生理鹽水灌胃,b.i.d)、芪癀膠囊組(1ml芪癀膠囊溶液灌胃,15.6mg/ml, b.i.d)、甲氨蝶呤組(1ml甲氨蝶呤溶液灌胃,3.9mg/ml,q.o.w)、聯(lián)合治療組(按芪癀膠囊及甲氨蝶呤各自給藥方法灌胃),每組8只,連續(xù)灌胃4周。觀察四組裸鼠骨肉瘤生長(zhǎng)情況：每周測(cè)量一次原位骨肉瘤體積,繪制骨肉瘤的生長(zhǎng)曲線,計(jì)算抑瘤率：其次,4周后取原位骨肉瘤組織,常規(guī)切片,HE染色,鏡下觀察骨肉瘤病理學(xué)情況；第三,通過(guò)免疫組化二步法檢測(cè)各組裸鼠原位瘤塊中Survivin, VEGF蛋白的表達(dá)情況。 結(jié)果： 1.骨肉瘤生長(zhǎng)抑制情況：與生理鹽水組相比,其他三組的骨肉瘤生長(zhǎng)均有明顯的減緩趨勢(shì)(P0.05),其中,芪癀膠囊加甲氨蝶呤聯(lián)合抑制骨肉瘤生長(zhǎng)療效最佳；芪癀膠囊組、甲氨蝶呤組和聯(lián)合治療組抑瘤率分別是18.01%、24.64%、37.90%,兩兩比較P0.05。 2.四組原位骨肉瘤Survivin、VEGF蛋白的表達(dá)情況：Survivin平均灰度值(IOD)分別為：73.39±1.27、49.29±0.91、37.98±0.85、23.04±0.53；VEGF的IOD值分別為：85.28±1.42、55.04±1.07、34.96±0.89、18.21±0.42。三治療組與生理鹽水組相比IOD值明顯降低,P0.05；兩兩比較P0.05。 結(jié)論：芪癀膠囊對(duì)原位移植骨肉瘤具有抑制作用,芪癀膠囊與甲氨蝶呤聯(lián)合治療時(shí),兩者具有協(xié)同作用,使抑瘤效果更佳。其機(jī)制可能是通過(guò)抑制骨肉瘤細(xì)胞中Survivin和VEGF的高表達(dá),從而誘導(dǎo)骨肉瘤細(xì)胞凋亡、降低骨肉瘤血管內(nèi)皮細(xì)胞的增殖和侵襲,從而達(dá)到抑制骨肉瘤生長(zhǎng)的效果。
[Abstract]:Objective: to observe the effect of Qihuang capsule on the growth of orthotopic transplantation osteosarcoma in nude mice and to explore its mechanism. Methods: the orthotopic transplantation model of osteosarcoma in 32 4-week-old BALB/c-nu/nu nude mice was established by injecting 5 脳 106 / 100 渭 l of JMR106-01 cell suspension into the right tibia after anesthesia. After successful identification of the model, the rats were randomly divided into four groups: saline group (1 ml) was given intragastric infusion of normal saline (1 ml), Qihuang capsule group (1 ml) was gavaged with 15.6 mg / ml, b.i.dg, methotrexate group (1 ml) of methotrexate solution was intragastrically perfused with 3.9 mg 路ml 路ml q.o.wn, and the combined treatment group (Qihuang capsule and Qihuang capsule) was treated by gavage. Methotrexate was administered intragastrically with 8 rats in each group. The volume of osteosarcoma in situ was measured once a week, the growth curve of osteosarcoma was drawn, and the tumor inhibition rate was calculated. The pathological changes of osteosarcoma were observed under microscope. Thirdly, the expression of survivin and VEGF protein was detected by immunohistochemical two-step method. Results:. 1. Growth inhibition of osteosarcoma: compared with normal saline group, the growth of osteosarcoma in the other three groups had a significant slowing trend (P 0.05), among which Qihuang capsule combined with methotrexate had the best effect on inhibiting the growth of osteosarcoma, and Qihuang capsule had the best effect on inhibiting the growth of osteosarcoma. The inhibitory rate of methotrexate group and combined treatment group were 18.01 and 24.647.90, respectively (P 0.05). 2. The expression of survivin protein in osteosarcoma in situ was: the mean gray value of survivin was: 73.39 鹵1.270.27, 49.29 鹵0.91g, 37.98 鹵0.853.04 鹵0.53. the IOD value of VEGF in the four groups was: 85.28 鹵1.42n 55.04 鹵1.0734.96 鹵0.8918.21 鹵0.422.The IOD value of the three treatment groups was significantly lower than that of the normal saline group (P0.055.05). Conclusion: Qihuang capsule has inhibitory effect on orthotopic transplantation of osteosarcoma, and Qihuang capsule and methotrexate have synergistic effect in the treatment of osteosarcoma. The mechanism may be to inhibit the growth of osteosarcoma by inhibiting the high expression of Survivin and VEGF in osteosarcoma cells, thus inducing the apoptosis of osteosarcoma cells and reducing the proliferation and invasion of vascular endothelial cells in osteosarcoma.
【學(xué)位授予單位】：福建中醫(yī)藥大學(xué)
【學(xué)位級(jí)別】：碩士
【學(xué)位授予年份】：2014
【分類號(hào)】：R273;R285.5

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 張俐;曾啟清;林建華;;P27基因聯(lián)合中藥片仔癀對(duì)人骨肉瘤抑制作用觀察[J];中華中醫(yī)藥雜志;2009年04期

2 黃永明;楊仁軒;蘇海濤;張嫻;許少健;徐逸生;;六味地黃湯對(duì)細(xì)胞誘導(dǎo)的殺傷細(xì)胞體外擴(kuò)增及抗骨肉瘤細(xì)胞的影響[J];中華中醫(yī)藥雜志;2011年10期

3 蘇海濤;黃永明;許少健;石宇雄;徐逸生;劉金文;;加味六味地黃湯對(duì)骨肉瘤化療患者免疫功能的影響[J];南方醫(yī)科大學(xué)學(xué)報(bào);2010年06期

4 徐強(qiáng);李朝旭;葉招明;;氯化兩面針堿對(duì)人骨肉瘤細(xì)胞的誘導(dǎo)凋亡作用及其機(jī)制[J];南方醫(yī)科大學(xué)學(xué)報(bào);2011年02期

5 曹平;陳春英;吳俊;張衛(wèi)國(guó);;雷帕霉素體外對(duì)骨肉瘤細(xì)胞生物學(xué)行為的影響及其分子機(jī)制[J];公共衛(wèi)生與預(yù)防醫(yī)學(xué);2012年04期

6 李偉;賀艷;張世權(quán);劉安慶;郝淑芹;;抑凋亡蛋白Survivin及P-糖蛋白在骨肉瘤中的表達(dá)與骨肉瘤化療耐藥性關(guān)系的研究[J];海南醫(yī)學(xué);2012年06期

7 頡玉欣;劉燕;張進(jìn)貴;李亞;郭曉華;趙萌;;白藜蘆醇誘導(dǎo)人成骨肉瘤細(xì)胞凋亡及其機(jī)制[J];河北醫(yī)藥;2007年04期

8 趙小明;薛新宏;趙少平;;骨肉瘤組織中Ang-2、VEGF的表達(dá)及MVD測(cè)定[J];鄭州大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2011年06期

9 尹軍強(qiáng);陳會(huì)明;羅文敏;沈靖南;鄭先玉;賈強(qiáng);;黃芩素與黃芩苷的體外抗骨肉瘤作用的比較[J];華西藥學(xué)雜志;2011年02期

10 吳慶;吳凱;馮瓊;付曉玲;;Survivin、Caspase-3、cyclinD1在骨肉瘤中的表達(dá)及臨床意義[J];南昌大學(xué)學(xué)報(bào)(醫(yī)學(xué)版);2010年01期

，

本文編號(hào)：1660878